Current Study
MASH | SF-CSP-002
The purpose of this study is to test the effectiveness and safety of the investigational medication in the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in at risk adults. This is a randomized, double-blind, placebo controlled and parallel group study of GL0034 (Utreglutide) for the treatment of (MASH).
Study Overview
Location
Spearwood, Osborne Park and Mandurah
Phase
2a
Study Duration
34 weeks
Main Entry Criteria
- 18 to 75 years of age
- BMI ≥ 30.0 kg  and ≤ 50 kg
- Liver fat content ≥ 8.5%
Main Exclusion Criteria
Assessments
- Medical and family history, including medicines, vitamins, and herbal supplements you takeÂ
- Vital signs like blood pressure, temperature, and pulse rate Â
- Height, weight, waist circumference, and physical examination Â
- Blood draws and urine collection for laboratory tests, Â
- Electrocardiogram (ECG)Â Â
- Magnetic resonance Imaging (MRI)Â Â
- FibroScan Â
At a Glance
Clinic Visits
41
Phone Calls
1
Duration
34 weeks